Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Article Details

Citation
Copy to clipboard

Ayeni D, Politi K, Goldberg SB

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Clin Cancer Res. 2015 Sep 1;21(17):3818-20. doi: 10.1158/1078-0432.CCR-15-1211. Epub 2015 Jul 13.

PubMed ID
26169963 [ View in PubMed
]
Abstract

Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.

DrugBank Data that Cites this Article

Drugs